leisure time -WSS

leisure time

author：comprehensive 2025-09-06 02:06:42 - browse：79539

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Kaiser Permanente unions announce official strike date

hotspot

WSS

FDA seeks to regulate lab

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Data show record exodus of life scientists from academia

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Ionis has late

Violet CEO on training clinicians to promote more inclusive care

leisure time

leisure time

leisure time

Medicare details structure of new drug price negotiation program

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Anesthesiologist group: stop taking Ozempic before surgery

Listen: Who gets the credit for GLP

Supreme Court strikes down use of affirmative action

Sudafed saga points to U.S. issues with evaluating older drugs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biogen shutters digital health group, ends Apple study, in cost cutting move

BioMarin wins approval for gene therapy to treat hemophilia A

Would Medicare drug price negotiations stall in a shutdown?

explore

After a drawn out lobbying fight, ARPA

Medicaid, Medicare dual

Data show record exodus of life scientists from academia

Violet CEO on training clinicians to promote more inclusive care

Bristol Myers buys into radiopharmaceuticals with RayzeBio

FDA seeks to regulate lab

hotspot

hotspot

hotspot

Wikipedia